|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2015
gptkb:FDA
|
|
gptkbp:atccode
|
L01 XE30
|
|
gptkbp:can_be_combined_with
|
gptkb:vemurafenib
|
|
gptkbp:casnumber
|
934660-93-0
|
|
gptkbp:chemical_formula
|
C19 H19 Cl F2 N4 O3 S
|
|
gptkbp:class
|
MEK inhibitor
|
|
gptkbp:clinical_trial
|
Cohort Study
Randomized Controlled Trial
Phase III
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to cobimetinib
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:drug_interactions
|
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:financial_support
|
report any signs of liver problems
avoid grapefruit products
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cotellic
|
|
gptkbp:indication
|
BRAF V600 E or V600 K mutation-positive melanoma
|
|
gptkbp:ingredients
|
gptkb:cobimetinib
|
|
gptkbp:is_monitored_by
|
electrolytes
liver function tests
|
|
gptkbp:manufacturer
|
gptkb:Genentech
|
|
gptkbp:market_position
|
currently marketed
|
|
gptkbp:marketed_as
|
gptkb:Cotellic
|
|
gptkbp:patient_population
|
gptkb:children
adults
|
|
gptkbp:pharmacokinetics
|
oral bioavailability
inhibits MEK1 and MEK2
|
|
gptkbp:related_products
|
gptkb:binimetinib
gptkb:selumetinib
gptkb:vemurafenib
gptkb:dabrafenib
gptkb:trametinib
|
|
gptkbp:research_focus
|
biomarkers
quality of life assessments
combination therapies
long-term outcomes
resistance mechanisms
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_measures
|
risk of blood clots
risk of eye problems
risk of serious skin reactions
risk of infections
risk of heart problems
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
liver problems
|
|
gptkbp:storage
|
store at room temperature
|
|
gptkbp:used_for
|
treatment of melanoma
|
|
gptkbp:bfsParent
|
gptkb:Roche_Pharma
|
|
gptkbp:bfsLayer
|
5
|